Home >> Marketplace Directory >> CMS extends coverage of Oncomine Dx test, 5/18

CMS extends coverage of Oncomine Dx test, 5/18

image_pdfCreate PDF

 

May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests. Combined with positive reimbursement decisions from commercial health insurers, the test is now available to more than 160 million people in the U.S.

The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.

Thermo Fisher Scientific, 866-356-0354

CAP TODAY
X